Aarti Drugs Ltd
AARTIDRUGSAarti Drugs Ltd
AARTIDRUGS
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 25.93 | 3.08 | 0.23% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.92 | 6.65 | 0.51% |
Forecast & Ratings
Detailed Forecast from 1 analyst
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Aarti Drugs Limited is a pharmaceutical company offering active pharmaceutical ingredients (APIs) in a range of therapeutic categories, such as anti-inflammatory, cardioprotectant, antifungals, antibiotic, antidiabetic, sedative and vitamins.
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,139.84 | 1,199.17 | 1,244.68 | 1,567.12 | 1,812.04 | 2,162.57 | 2,499.97 | 2,718.24 | 2,532.61 | 2,384.94 | ||||||||||
Raw Materials | 758.16 | 765.89 | 821.92 | 1,026.31 | 1,210.60 | 1,310.66 | 1,750.06 | 1,863.71 | 1,626.10 | 2,091.64 | ||||||||||
| Power & Fuel Cost | 53.93 | 59.42 | 71.42 | 84.39 | 103.83 | 98.20 | 128.34 | 156.10 | 154.31 | |||||||||||
| Employee Cost | 40.19 | 47.95 | 52.14 | 54.55 | 61.35 | 65.88 | 69.30 | 80.43 | 90.60 | |||||||||||
| Selling & Administrative Expenses | 37.92 | 41.74 | 47.60 | 54.66 | 80.16 | 98.43 | 104.24 | 104.66 | 95.12 | |||||||||||
| Operating & Other expenses | 69.83 | 89.69 | 48.68 | 130.12 | 84.63 | 144.28 | 104.11 | 201.71 | 241.61 | |||||||||||
EBITDA | 179.81 | 194.48 | 202.92 | 217.09 | 271.47 | 445.12 | 343.92 | 311.63 | 324.87 | 293.30 | ||||||||||
| Depreciation/Amortization | 36.53 | 38.46 | 40.06 | 42.56 | 48.75 | 49.88 | 50.05 | 50.32 | 51.45 | 53.34 | ||||||||||
| PBIT | 143.28 | 156.02 | 162.86 | 174.53 | 222.72 | 395.24 | 293.87 | 261.31 | 273.42 | 239.96 | ||||||||||
| Interest & Other Items | 48.02 | 40.02 | 38.36 | 43.51 | 37.42 | 26.23 | 23.91 | 37.14 | 37.89 | 34.37 | ||||||||||
| PBT | 95.26 | 116.00 | 124.50 | 131.02 | 185.30 | 369.01 | 269.96 | 224.17 | 235.53 | 205.59 | ||||||||||
| Taxes & Other Items | 26.55 | 34.21 | 42.20 | 41.27 | 43.89 | 88.60 | 64.92 | 57.88 | 64.10 | 53.30 | ||||||||||
| Net Income | 68.71 | 81.79 | 82.30 | 89.75 | 141.41 | 280.41 | 205.04 | 166.29 | 171.43 | 152.29 | ||||||||||
| EPS | 7.09 | 8.51 | 8.67 | 9.51 | 15.08 | 30.09 | 22.07 | 17.96 | 18.58 | 16.56 | ||||||||||
| DPS | 1.69 | 0.25 | 0.25 | 0.25 | 0.50 | 2.50 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||||
| Payout ratio | 0.24 | 0.03 | 0.03 | 0.03 | 0.03 | 0.08 | 0.05 | 0.06 | 0.05 | 0.06 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFInvestor Presentation
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Aarti Drugs Ltd | 23.03 | 3.08 | 0.23% |
| Sun Pharmaceutical Industries Ltd | 45.12 | 6.44 | 0.75% |
| Cipla Ltd | 28.85 | 4.44 | 0.88% |
| Torrent Pharmaceuticals Ltd | 69.10 | 16.69 | 0.83% |
Price Comparison
Compare AARTIDRUGS with any stock or ETFShareholdings
Promoter Holdings Trend
Decreased Total Promoter Holding
In last 6 months, promoter holding in the company has decreased by 1.49%
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Aarti Drugs Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
DSP Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 5.6765% | Percentage of the fund’s portfolio invested in the stock 1.37% | Change in the portfolio weight of the stock over the last 3 months -0.26% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 27/79 (-2) |
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Plan Growth Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.2288% | Percentage of the fund’s portfolio invested in the stock 0.96% | Change in the portfolio weight of the stock over the last 3 months 0.96% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 34/51 (+17) |
DSP Healthcare Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.8565% | Percentage of the fund’s portfolio invested in the stock 1.04% | Change in the portfolio weight of the stock over the last 3 months -0.43% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 23/32 (-3) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Trend In Dividends
AARTIDRUGS has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Current dividend yield is 0.23%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹2.33 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateFeb 6, 2024
Dividend/Share
₹1.00
Ex DateEx Date
Feb 6, 2024
Cash Dividend
Ex DateEx DateFeb 8, 2023
Dividend/Share
₹1.00
Ex DateEx Date
Feb 8, 2023
Cash Dividend
Ex DateEx DateFeb 9, 2022
Dividend/Share
₹1.00
Ex DateEx Date
Feb 9, 2022
Cash Dividend
Ex DateEx DateNov 3, 2020
Dividend/Share
₹2.50
Ex DateEx Date
Nov 3, 2020
Cash Dividend
Ex DateEx DateFeb 17, 2020
Dividend/Share
₹2.00
Ex DateEx Date
Feb 17, 2020
Net profit of Aarti Drugs declined 11.57% to Rs 35.01 crore in the quarter ended September 2024 as against Rs 39.59 crore during the previous quarter ended September 2023. Sales declined 6.74% to Rs 598.33 crore in the quarter ended September 2024 as against Rs 641.54 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales598.33641.54 -7 OPM %11.2111.92 - PBDT59.6068.88 -13 PBT45.8856.27 -18 NP35.0139.59 -12 Powered by Capital Market - Live
Aarti Drugs will hold a meeting of the Board of Directors of the Company on 24 October 2024.Powered by Capital Market - Live
The company said that there are no financial or material impacts as of now. With the GMP compliance, Pinnacle is positioned to export its formulations to the UK market. The firm stated that there have been no violations or alleged contraventions regarding its operations. Aarti Drugs is primarily involved in manufacturing and marketing of Active Pharmaceutical Ingredients (API), Pharma Intermediates and Specialty Chemicals. The company's consolidated net profit declined 30.5% to Rs 33.24 crore on 16% slide in net sales to Rs 555.34 crore in Q1 FY25 over Q1 FY24.Powered by Capital Market - Live
The API inspection was conducted from 12 September to 20 September 2024. At the conclusion of the inspection, the USFDA issued a Form FDA 483, which included seven inspectional observations. Notably, none of the observations were related to data integrity. The company stated that it will work closely with USFDA to resolve all points raised during the inspection. Aarti Drugs is primarily involved in manufacturing and marketing of Active Pharmaceutical Ingredients (API), Pharma Intermediates and Specialty Chemicals. The company's consolidated net profit declined 30.5% to Rs 33.24 crore on 16% slide in net sales to Rs 555.34 crore in Q1 FY25 over Q1 FY24. The scrip advanced 1.16% to ends at Rs 524.80 on Friday, 20 September 2024.Powered by Capital Market - Live
Aarti Drugs announced that the bidding process of buyback offer will remain open on Monday, 16 September 2024 (SEBI working day) and close tender offer on Thursday, 19 September 2024 (except Wednesday, 18 September 2024, being holiday). Powered by Capital Market - Live
Aarti Drugs announced that the Annual General Meeting (AGM) of the company will be held on 20 September 2024.Powered by Capital Market - Live
The Board of Aarti Drugs at its meeting held on 26 August 2024 has approved buyback of up to 6,65,000 equity shares of face value of Rs 10 each at a price of Rs 900 per share payable in cash for an aggregate amount of up to Rs 59.85 crore. Powered by Capital Market - Live
Aarti Drugs has fixed 05 September 2024 as record date for proposed buyback of shares. Powered by Capital Market - Live
The buyback price fixed at Rs 900 per equity share, representing a 59.66% premium to Friday's closing price of Rs 563.70 on the BSE. The pharmaceutical company will buyback up to 6, 65,000 fully paid-up equity shares, representing up to 0.72% of the total paid-up equity shares of the firm. The buyback offer size represents 5.16% and 4.74% of the fully paid- up equity share capital and free reserves of the company based on the audited standalone and consolidated balance sheet of the company as on 31 March 2024, respectively. The company has fixed 5 September 2024 as the record date for the proposed buyback. The public announcement setting out the process, timelines and other requisite details will be released in due course in accordance with the buyback regulations, said the firm. Aarti Drugs is primarily involved in manufacturing and marketing of Active Pharmaceutical Ingredients (API), Pharma Intermediates and Specialty Chemicals. The company's consolidated net profit declined 30.5% to Rs 33.24 crore on 16% slide in net sales to Rs 555.34 crore in Q1 FY25 over Q1 FY24. The counter hit a 52-week high of Rs 632.10 in today's intraday session. Powered by Capital Market - Live
The announcement was made after market hours yesterday. Aarti Drugs forms part of $6 Billion Aarti Group of Industries with robust R&D Division at Tarapur, Maharashtra Industrial Development Corporation (MIDC) in close vicinity to manufacturing locations. The company is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Speciality Chemicals and produces Formulations with its whollyowned subsidiary-Pinnacle Life Science Private. The company's consolidated net profit declined 30.5% to Rs 33.24 crore on 16% slide in net sales to Rs 555.34 crore in Q1 FY25 over Q1 FY24. Powered by Capital Market - Live
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 10.08%, vs industry avg of 9.03%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.71% to 0.67%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 13.82%, vs industry avg of 15.27%